Overview
My clinical interests include systemic lupus erythematosus (SLE) and inflammatory myopathies. In 2007, I co-founded the Duke Lupus Clinic with Dr. Megan Clowse. We have continued this clinic with the aim to improve the health and quality of life for individuals living with lupus. In 2024, I co-founded the Duke Myositis Clinic with Dr. Nathaniel Harris. Similarly, we aim to improve the health, function, and quality of life for individuals living with inflammatory myopathies.
My primary research interests are in education and in SLE. My particular interest within education is learner assessment. I was previously funded by a Clinician Scholar Educator Award through the Rheumatology Research Foundation of the American College of Rheumatology. My CSE project explored validation of a rheumatology objective structured clinical examination (ROSCE). I continue to collaborate with the Rheumatology Program Directors at UNC Chapel Hill, Wake Forest University, the Medical University of South Carolina and Massachusetts General Hospital through our Carolinas Fellows Collaborative. Members of this group composed the competency-based goals and objectives (CBGO) for all learning activities of rheumatology fellowship training programs, which were adopted by the American College of Rheumatology and are posted on their website. I have been very involved in rheumatology curricular efforts through the American College of Rheumatology. I served on the Milestones working group and am a past member and past Chair of the ACR Curriculum Subcommittee of the Committee on Training and Workforce. I previously participated on the ACR/NBME rheumatology in-training examination working group.
Clinical research in lupus has included the Duke Lupus Registry population. Our recent work focuses on creating and defining the type 1 and type 2 lupus paradigms for classifying lupus disease activity. Additional interests through the Duke Lupus Clinic include elucidating clinician-level factors that can influence medication adherence as well as determining how health literacy and numeracy impact adherence and patient level outcomes. I collaborate with Dr. Megan Clowse, who studies reproductive health in women with autoimmune diseases. We have combined her subject matter expertise with my educational skills to create HOP-STEP, a program to teach patients with lupus and their rheumatologists about pregnancy planning to improve health outcomes. We have created lupuspregnancy.org, which houses many resources and videos designed to teach rheumatologists to better partner with women with lupus to have open and honest discussions about pregnancy planning. Our ultimate aim is to improve the health outcomes for women with lupus and their offspring.
Current Duke Appointments & Affiliations
Recent Scholarly Works
A quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic
Conference Lupus · August 1, 2026 Background/Purpose: Mycophenolate compound (MMF, to represent both mycophenolate mofetil and mycophenolic acid) is an immunosuppressant used to treat Systemic Lupus Erythematosus (SLE). Due to its teratogenicity, the FDA recommends universal mycophenolate ... Full text CiteA quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic.
Journal article Lupus · August 2026 Background/PurposeMycophenolate compound (MMF, to represent both mycophenolate mofetil and mycophenolic acid) is an immunosuppressant used to treat Systemic Lupus Erythematosus (SLE). Due to its teratogenicity, the FDA recommends universal mycophenolate Ri ... Full text Link to item CiteIt's never lupus: Hemophagocytic lymphohistiocytosis secondary to Ehrlichia chafeensis mimicking a lupus flare.
Journal article Am J Med · June 6, 2026 Full text Link to item CiteRecent Grants
DRA02 - A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)
Clinical TrialPrincipal Investigator · Awarded by Allogene Therapeutics, Inc. · 2025 - 2035JASMINE
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2031Evaluation of a Lupus Nephritis Care Pathway Integrating Telemedicine and Clinical Pharmacist Practitioners
ResearchCo-Principal Investigator · Awarded by Rheumatology Research Foundation · 2026 - 2028View All Grants